Tekla Life Sciences Investors (HQL) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Tekla Life Sciences Investors (HQL) has a cash flow conversion efficiency ratio of -0.002x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.22 Million) by net assets ($560.83 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Tekla Life Sciences Investors market cap and net worth for the company's overall valuation and market capitalisation.
Tekla Life Sciences Investors - Cash Flow Conversion Efficiency Trend (1996–2025)
This chart illustrates how Tekla Life Sciences Investors's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Tekla Life Sciences Investors Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Tekla Life Sciences Investors ranked by their cash flow conversion efficiency. Explore HQL cash flow quality score to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
TrueLight
TWO:3234
|
-0.033x |
|
OneSpan Inc
NASDAQ:OSPN
|
0.000x |
|
Guangdong Sunwill Precising Plastic Co Ltd
SHE:002676
|
0.060x |
|
Jana Small Finance Bank
NSE:JSFB
|
-0.575x |
|
Orchid Pharma Limited
NSE:ORCHPHARMA
|
0.009x |
|
Sido Muncul PT
JK:SIDO
|
0.055x |
|
Hangzhou Anysoft Information Technology Co Ltd
SHE:300571
|
0.066x |
|
Stylam Industries Limited
NSE:STYLAMIND
|
0.104x |
Annual Cash Flow Conversion Efficiency for Tekla Life Sciences Investors (1996–2025)
The table below shows the annual cash flow conversion efficiency of Tekla Life Sciences Investors from 1996 to 2025. View Tekla Life Sciences Investors share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-09-30 | $513.66 Million | $-2.32 Million | -0.005x | -319524554.28% |
| 2021-09-30 | $523.44 Million | $-0.74 | 0.000x | +12.40% |
| 2019-09-30 | $384.16 Million | $-0.62 | 0.000x | +100.00% |
| 2014-09-30 | $444.09 Million | $-52.57K | 0.000x | -477.75% |
| 2013-09-30 | $302.29 Million | $9.47K | 0.000x | -99.97% |
| 2012-09-30 | $227.08 Million | $21.11 Million | 0.093x | -86.60% |
| 2011-09-30 | $170.60 Million | $118.30 Million | 0.693x | +9075.24% |
| 2010-09-30 | $251.40 Million | $1.90 Million | 0.008x | -85.55% |
| 2009-09-30 | $248.60 Million | $13.00 Million | 0.052x | +23.11% |
| 2008-09-30 | $277.80 Million | $11.80 Million | 0.042x | +453.59% |
| 2007-09-30 | $308.00 Million | $-3.70 Million | -0.012x | -53.37% |
| 2006-09-30 | $268.10 Million | $-2.10 Million | -0.008x | +43.87% |
| 2005-09-30 | $229.30 Million | $-3.20 Million | -0.014x | +16.35% |
| 2004-09-30 | $191.80 Million | $-3.20 Million | -0.017x | -32.36% |
| 2003-09-30 | $190.40 Million | $-2.40 Million | -0.013x | +23.59% |
| 2002-09-30 | $157.60 Million | $-2.60 Million | -0.016x | -86.77% |
| 2001-09-30 | $215.10 Million | $-1.90 Million | -0.009x | +48.04% |
| 1998-09-30 | $100.00 Million | $-1.70 Million | -0.017x | -49.60% |
| 1997-09-30 | $132.00 Million | $-1.50 Million | -0.011x | +6.74% |
| 1996-09-30 | $123.10 Million | $-1.50 Million | -0.012x | -- |
About Tekla Life Sciences Investors
Abrdn Life Sciences Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, … Read more